Scenarios that move HIMS
Hims & Hers Health, Inc. Class A Common Stock
Scenarios that move HIMS: 13 analyses, 5 positive, 8 negative.
- · Viking Therapeutics advances oral obesity drug to Phase III — ▲ · impact +10 · confidence low · horizon quarters
- · Hims & Hers faces securities fraud class action after FTC lawsuit — ▼ · impact -93 · confidence medium · horizon immediate
- · Zealand Pharma reports positive survodutide Phase III weight loss results — ▼ · impact -20 · confidence low · horizon quarters
- · Novo Nordisk's Ozempic outperforms Lilly's Mounjaro on cardiovascular risk — ▲ · impact +48 · confidence low · horizon weeks
- · Lilly reports strong weight loss results for new drug — ▼ · impact -48 · confidence low · horizon quarters
- · Novo and Hengrui sign exclusive license for oral GLP-1/GIP drug — ▲ · impact +18 · confidence low · horizon quarters
- · Pharma stock soars 150% after injectables deal with Novo — ▼ · impact -34 · confidence low · horizon quarters
- · ◇ What if… Oral GLP-1 drugs replace injectable treatments — ▲ · impact +44 · confidence low · horizon quarters
- · Viking Therapeutics stock skyrockets in Tuesday trading — ▼ · impact -22 · confidence low · horizon quarters
- · ◇ What if… Samuel Alito announces retirement by December 31, 2026 — ▼ · impact -35 · confidence low · horizon quarters
- · Definium reports second Phase III success in anxiety program — ▼ · impact -10 · confidence low · horizon quarters
- · Waldencast announces plan to delist from Nasdaq — ▲ · impact +10 · confidence low · horizon quarters
- · Eli Lilly Weight Loss Pill Shows Better Results Than Injectable Competitors In Phase 3 Trial — ▼ · confidence medium